TRexBio Raises $50M for Clinical Treg Therapeutics Pipeline
TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company discovering and developing precision immunoregulatory medicines based on tissue Treg biology, today announced the close of an oversubscribed...